Quince Therapeutics, Inc. (QNCX)
- Previous Close
0.9500 - Open
0.9215 - Bid 0.8713 x 100
- Ask 0.9795 x 100
- Day's Range
0.9002 - 0.9500 - 52 Week Range
0.8400 - 1.7400 - Volume
59,172 - Avg. Volume
76,440 - Market Cap (intraday)
39.745M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8400 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
www.quincetx.comRecent News: QNCX
Performance Overview: QNCX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QNCX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QNCX
Valuation Measures
Market Cap
41.05M
Enterprise Value
-20.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.44
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.33%
Return on Equity (ttm)
-33.81%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-31.39M
Diluted EPS (ttm)
-0.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
75.06M
Total Debt/Equity (mrq)
16.24%
Levered Free Cash Flow (ttm)
-1.94M
Research Analysis: QNCX
Company Insights: QNCX
QNCX does not have Company Insights